Bitcoin remains flat near $64,000 despite global stock indexes reaching record highs driven by AI optimism and easing geopolitical tensions. Crypto-specific weakness is evident as U.S. spot bitcoin ETFs saw $5.4 billion in net outflows in H1 2026, with capital rotating into AI-linked assets. Derivatives data show subdued activity in bitcoin and ether futures but aggressive buying in select altcoins. Notably, Tether's market cap contracted sharply by $4 billion over 60 days, signaling capital leaving crypto and possibly marking late-stage selling. A sustained crypto recovery would require Tether's supply to increase again. Upcoming U.S. economic data may influence market direction.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
